Full-Time

Director – Pharma Payer Marketing New Products

Posted on 4/14/2025

Merck

Merck

10,001+ employees

Develops medicines and vaccines for health issues

No salary listed

Senior

No H1B Sponsorship

North Wales, PA, USA

Hybrid work model requires three days in the office and one day remote.

Category
General Marketing
Growth & Marketing
Required Skills
Agile
Marketing
Requirements
  • BA/BS
  • Minimum of 5 years marketing, payer and/or account management experience.
  • Demonstrated understanding of the mechanics, influencers and economics of US healthcare ecosystem.
  • Demonstration of strategy development, scenario planning and guidance of pull through execution.
  • Strong leadership and influencing skills.
  • Demonstrated track record of building and leading high performing teams, including agile teams.
Responsibilities
  • Coach, develop and guide a high performing team of payer marketing associate directors through competency development and coaching
  • Work closely with Global Marketing, Global Market Access, US New Products, and Business Development to provide a point of view on payer access for pipeline products and business development targets
  • Leverage market and customer insights to shape market access strategies
  • Develop payer customer segment strategy to inform forecast and choices regarding future products
  • Support US Finance in the development of forecasts
  • Develop payer value propositions, pricing and contracting strategies
  • Active participation in the development of value evidence strategies; strong coordination with Outcomes Research / V&I (Value & Implementation Team)
Desired Qualifications
  • Knowledge of digital platforms for customer analytics and customer engagement.
  • Account Management/Contract Negotiation experience.
  • Experience spanning functional boundaries to effectively prioritize work and build partnerships.

Merck develops medicines and vaccines to address significant health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck generates revenue through the sale of prescription medications, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance programs, which provide free medicines and vaccines to eligible patients. Additionally, Merck supports healthcare professionals with resources like Merck Connect and Merck Manuals, distinguishing itself from competitors by its comprehensive support for both patients and healthcare providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's $1 billion investment in vaccine manufacturing boosts production capabilities.
  • The Cyprumed deal enhances Merck's peptide drug delivery systems.
  • Merck's positive Phase 3 results for subcutaneous Pembrolizumab strengthen its oncology portfolio.

What critics are saying

  • Increased competition from AstraZeneca and Novo Nordisk threatens Merck's market share.
  • Potential legal issues related to securities could impact Merck's financial standing.
  • Data privacy challenges may affect trust in Merck's AI-driven healthcare collaborations.

What makes Merck unique

  • Merck is recognized as a Digital Health Innovation Leader since 2023.
  • Merck's collaboration with Microsoft integrates AI-driven medical information into healthcare services.
  • Merck's R&D focuses on innovative treatments for cardiovascular, diabetes, and cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

Sandra Gona
Apr 16th, 2025
India logs 2,430 new Covid cases_Spider information

As a result of these efforts, Merck has been recognized as a "Digital Health Innovation Leader" for two consecutive years since 2023.

BioSpace
Apr 15th, 2025
Merck Eyes Oral Peptide Delivery With Cyprumed Deal Worth up to $493M

Merck on Tuesday entered into a nonexclusive licensing and option pact with Austrian biotech Cyprumed in a bid to make its peptide drugs orally available.

PR Newswire
Apr 14th, 2025
Merck Manuals To Collaborate With Microsoft To Integrate Medical Information Resources Into Healthcare Agent Service In Microsoft Copilot Studio

RAHWAY, N.J., April 14, 2025 /PRNewswire/ -- The Merck Manuals is pleased to announce its collaboration with Microsoft to integrate its esteemed professional medical reference into healthcare agent service in Microsoft Copilot Studio. This exciting initiative harnesses the power of Generative AI (GenAI) to provide clinicians with trusted, comprehensive, and evidence-based medical content at the point of care.The Merck Manuals is proud to be an independent (non-government) medical information resource integrated into this platform. This collaboration exemplifies a commitment to enhancing clinical workflows by incorporating Merck Manuals' authoritative content into Microsoft's healthcare agent service in Copilot Studio. This integration empowers healthcare technology developers to create generative AI-driven healthcare agents that leverage this high-value content to grant clinicians immediate access to vital medical information."Clinicians and healthcare organizations worldwide depend on the Merck Manuals and MSD Manuals for accurate and reliable answers to their clinical questions," stated Dr. Sandy Falk, Editor-in-Chief of the Merck Manuals. "Through this collaboration with Microsoft, we are building solutions to deliver our comprehensive, evidence-based content to meet the needs of healthcare professionals

APP
Apr 14th, 2025
Novartis plans $23B expansion of manufacturing in US, including North Jersey site

Merck announced plans to spend $1 billion on a vaccine manufacturing site in North Carolina, plus $8 billion on other upgrades.

PRWeb
Apr 12th, 2025
The Melanoma Research Foundation To Host The Dc Miles For Melanoma 5K

The Melanoma Research Foundation (MRF) is thrilled to announce one of the first events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual DC event on Saturday, May 3, 2025 at Yards Park at 7:30 AM ET. Opening Ceremonies will start at 8:30 AM ET and our race will kick off promptly at 9:00 AM ET. We are excited to share that Ian Michael Crumm, Celebrity Esthetician, will be joining us on event day as our emcee!WASHINGTON, April 12, 2025 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce one of the first events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual DC event on Saturday, May 3, 2025 at Yards Park at 7:30 AM ET. Opening Ceremonies will start at 8:30 AM ET and our race will kick off promptly at 9:00 AM ET